Eylea
Eylea receives new European approval
August 30, 2013Research and Development, Sales and Marketing Bayer, CRVO, Eylea, Lucentis, Novartis, wet AMD
Eylea trial boost in DME
August 7, 2013Research and Development, Sales and Marketing Bayer, DME, Eylea, regenenron
The rival treatment to Novartis’ Lucentis has posted encouraging new study results in patients with diabetic macular oedema (DME). In …
New price and data changes NICE view on Lucentis
January 4, 2013Sales and Marketing Bayer, Eylea, Lucentis, NICE, Novartis
A new lower price and new data analysis has persuaded NICE to recommend Lucentis for patients with diabetic macular oedema …
Eylea approval for wet AMD
November 29, 2012Sales and Marketing Bayer, Eylea, Lucentis, Novartis, avastin, wet AMD
Bayer HealthCare’s Eylea has been appoved in Europe for the treatment of neovascular age-related macular degeneration (wet AMD). The eye …
Lucentis gains new licence in the US
August 13, 2012Sales and Marketing Eylea, FDA, Lucentis, approval, avastin, wet AMD
Roche’s eye drug Lucentis has gained a new licence in the US to treat diabetic macular oedema. The FDA has …
Regeneron to expand workforce at New York facility
August 8, 2012Manufacturing and Production Arcalyst, Eylea, Regeneron, Zaltrap
Buoyant product sales at US biotech Regeneron have prompted the company to undertake a recruitment drive at its manufacturing facility …
Major new drugs for 2012
March 9, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Caprelsa, Eylea, Manjor new drugs, Xalkori, Zelboraf, avastin, inlyta
Renal cell carcinoma Pfizer’s Inlyta (axitinib) has been approved as second line treatment for renal cell carcinoma. The drug is …
Key product launches of 2011
December 19, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products
Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …
Lucentis rival gains US approval
November 22, 2011Research and Development, Sales and Marketing Bayer, Eylea, Lucentis, Novartis, Regeneron, Roche
A rival to Roche and Novartis’ drug Lucentis has received FDA approval for a common form of eye disease. Eylea …
Latest content
FibroFind appoints Lee Borthwick as CEO
